tiprankstipranks
Advertisement
Advertisement

GANX Stock Latest News

Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
RatingsGain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
6d ago
GANX
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
PremiumRatings
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
7d ago
GANX
Closing Bell Movers: AeroVironment jumps after quarterly report
PremiumThe Fly
Closing Bell Movers: AeroVironment jumps after quarterly report
9d ago
TW
AVAV
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
PremiumCompany Announcements
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
9d ago
8K
GANX
Gain Therapeutics receives FDA clearance of GT-02287 IND application
PremiumThe Fly
Gain Therapeutics receives FDA clearance of GT-02287 IND application
9d ago
GANX
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
PremiumCompany AnnouncementsGain Therapeutics Shareholders Confirm Board and Auditor Choices
13d ago
8K
GANX
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
Premium
Ratings
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
1M ago
GANX
Gain Therapeutics presents data from Phase 1b study of GT-02287
Premium
The Fly
Gain Therapeutics presents data from Phase 1b study of GT-02287
1M ago
GANX
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
PremiumCompany Announcements
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
1M ago
8K
GANX
Is GANX a Buy, Before Earnings?
PremiumPre-Earnings
Is GANX a Buy, Before Earnings?
2M ago
GANX
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
PremiumRatings
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
2M ago
GANX
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
PremiumThe Fly
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
2M ago
GANX
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
PremiumThe FlyGain Therapeutics reports Q1 EPS (13c), consensus (14c)
2M ago
GANX
Gain Therapeutics management to meet with Maxim
Premium
The Fly
Gain Therapeutics management to meet with Maxim
3M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
3M ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
3M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
PremiumCompany Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
4M ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
4M ago
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
4M ago
GANX
Gain Therapeutics provides regulatory update on GT-02287
PremiumThe FlyGain Therapeutics provides regulatory update on GT-02287
4M ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
6M ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
Premium
Ratings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
6M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >